Merck Discontinues Bacterial Infection Drug in Europe
Key takeaways
- Merck is pulling Zinplava from the EU and U.S., ending a therapy that helped prevent recurrent Clostridium difficile infections.
- Zinplava approved 2017
- Unlimited validity 2021
- Pediatric extension December 2023
What happened
Merck & Co Inc. (MRK) has permanently stopped selling its bacterial infection drug Zinplava (bezlotoxumab) in Europe after the European Commission withdrew its marketing authorization. The drug had been approved in 2017 to prevent repeat Clostridium difficile infections in high‑risk adults, later extended to children in 2023. The withdrawal follows a direct notification from Merck’s European arm and coincides with the company’s planned U.S. exit in December 2024.
Why it matters
The loss of Zinplava in the EU removes a key treatment option for preventing recurrent Clostridium difficile infections, a serious and costly condition. It signals Merck’s strategic shift away from this therapy globally, potentially affecting its revenue streams and market positioning in the infectious disease space.…
Short-term and longer-term
Short-term. Merck shares jumped 3.19% after the EU withdrawal announcement.
Longer-term. Over the next few months, investors should monitor how Merck reallocates resources from Zinplava to other therapeutic areas.